A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need

Informazioni relative al progetto

ATx201

ID dell’accordo di sovvenzione: 736508

DOI

10.3030/736508

Progetto chiuso

Data della firma CE 11 Luglio 2016

Data di avvio 1 Agosto 2016

Data di completamento 30 Novembre 2016

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

UNION THERAPEUTICS AS
Denmark

Periodic Reporting for period 1 - ATx201 (A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need)

Periodo di rendicontazione: 2016-08-01 al 2016-11-30

Sintesi del contesto e degli obiettivi generali del progetto

Atopic dermatitis (AD) is associated with significant co-morbidity. The solution provided by AntibioTx represents a new mode of action. The objectives of the project are to verify the promise of the drug product and advance commercial understanding to bring the solution to market.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

The current stage of development of the proposed solution aligns with a Technology Readiness Level 7 since the drug compound had been tested on human subject volunteers. The project helped to establish the definition development plans for the solution in questions. This includes assessment of regulatory route, interaction with regulatory consultants and competent authorities, as well as clinical study design to bring forward its market authorisation agenda. This process has been developed with clinical advisors and KOLs within dermatology.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The project is designed to demonstrate how the solution in question can contribute to address the medical need in atopic dermatitis and offer a better treatment due to the new mode of action. Early data provides evidence for the potential to change the treatment paradigm of dermatological diseases by providing an innovative and significantly differentiated treatment.

fotolia-114431753-subscription-monthly-m.jpg

boksbillede1.jpg